Arizona Tribune - BioLargo Demonstrates Over 99% Removal of Ultrashort-Chain PFAS Including TFA Using Aqueous Electrostatic Concentration Technology

This breakthrough marks a significant milestone in the fight against PFAS pollution, particularly for compounds like TFA that have eluded conventional treatment methods due to their small molecular size and high solubility.

"Ultrashort-chain PFAS are among the most challenging to capture and remove," said Randall Moore, President of BioLargo Water. "Our AEC technology has now demonstrated the ability to concentrate and eliminate these compounds with unprecedented efficiency. This further positions BioLargo as a leader in the current and next-generation PFAS treatment industry."

The company's internal testing, conducted in collaboration with third-party laboratories, confirms that AEC consistently removes TFA and other ultra-short chain PFAS at rates exceeding 99%, without generating harmful byproducts or secondary waste streams. These results build on BioLargo's previously validated performance with long-chain PFAS such as PFOA and PFOS. The BioLargo solution allows for the efficient removal and concentrated collection process of PFAS, which is then followed by a propriety destruction technique.

BioLargo's AEC system uses electrostatic forces to selectively attract and isolate charged contaminants from water, enabling scalable, energy-efficient treatment across a wide range of PFAS profiles. The technology is currently being deployed commercially in North America.

"This is a game-changer for communities and any industry grappling with PFAS contamination," said Dennis P. Calvert, CEO of BioLargo. "We now have solid evidence in hand that our technology can tackle the full spectrum of PFAS compounds-including the ultra-short-chain molecules that others leave behind. We are actively engaged in discussions with potential partners and customers to begin ramping up our commercial activities."

About BioLargo, Inc.

BioLargo, Inc. (OTCQX:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com.

Contact Information for BioLargo, Inc.

Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863

For more information to learn about our PFAS Solutions:

Contact: Tonya Chandler
President BioLargo Equipment
[email protected]
(608) 397-8301

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo's (the "Company") expectations regarding anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of regional economic conditions on the Company's business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company's products. More information on these risks and other potential factors that could affect the Company's business and financial results is included in the Company's filings with the SEC, including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

SOURCE: BioLargo, Inc

View the original press release on ACCESS Newswire

M.Robinson--AT